Skip to main content
. 2017 Apr 24;48(5):1262–1270. doi: 10.1161/STROKEAHA.116.014321

Figure 1.

Figure 1.

Patient flow diagram. The numbers presented are as treated. There were 2 patients who were randomized to the placebo group but received an incorrect kit, which after unblinding was determined to have contained Actovegin. Those patients are included as randomized for the intent-to-treat (ITT) analyses (placebo group) and as treated for the safety analyses (Actovegin group). More than 1 reason for discontinuation could have been selected.